Search Results
49 Results for 'Vaccines'
PAGE 2 OF 2
Technology
Mini-Intronic Plasmid Dna Vaccines In Combination With Lag3 Blockade
It is disclosed herein that (a) an anti-tumor DNA vaccine delivered using a MIP DNA vector is a less effective tumor treatment than the corresponding anti-tumor DNA vaccine delivered using a conventio...
Learn More
Learn More
Douglas McNeel, Viswa Colluru | P150088US02
Technology
HLF-VC1 Master Cell Bank for Vaccine Development
FDA-qualified cell lines must be used for virus production for human vaccines. There are relatively few of these lines available and several (WI-38, MRC-5) used for virus production are becoming senes...
Learn More
Learn More
James Gern | P160170US01
Technology
TLR Agonists for Reducing Activation-Induced PD-1 Expression on T Cells, Improved Anti-Tumor Response
Current anti-cancer DNA vaccines are safe and immunologically effective, but would be still more effective if they could elicit a stronger anti-tumor response and require fewer administrations. For th...
Learn More
Learn More
Douglas McNeel, Christopher Zahm | P170048US02
Technology
Improved Influenza B Virus Replication for Vaccine Development
The epidemiology of influenza Type B viruses differs from Type A; influenza B viruses primarily circulate in humans and do not cause pandemics. However, in some seasons the impact of influenza B infec...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P160181US02
Technology
Mutations That Improve Genetic Stability of Influenza Virus for Vaccination, Gene Therapy & More
The influenza virus is a highly contagious respiratory pathogen that causes annual epidemics and occasional pandemics. Although many studies have looked at how a host responds to infection with the vi...
Learn More
Learn More
Yoshihiro Kawaoka, Satoshi Fukuyama, Shinji Watanabe | P140264US02
Technology
Efficient Generation of Influenza Virus with Adenoviral Vectors
Influenza is responsible for hundreds of thousands of deaths worldwide every year. Vaccines can be used to prevent influenza, but traditional methods for producing influenza vaccine are slow and cumbe...
Learn More
Learn More
Yoshihiro Kawaoka, Makoto Ozawa | P06444US
Technology
Influenza Variant Grows Well in CHO Cells
Vaccines against influenza and other viruses can be grown in Chinese Hamster Ovary (CHO) cells. Problematically, an influenza virus that is made by combining H1N1 and PR8 strains, and that is recommen...
Learn More
Learn More
Yoshihiro Kawaoka, Makoto Ozawa | P100246US02
Technology
Neuraminidase-Deficient Live Influenza Vaccine
Influenza infects up to 20 percent of the world’s population every year, causing 500,000 deaths and costing tens of billions of dollars in medical expenses. Influenza A virus, which causes pandemics...
Learn More
Learn More
Yoshihiro Kawaoka, Masato Hatta | P07044US
Technology
Vaccine for Fungal Infections
There are no commercial vaccines against fungi. Infections like aspergillosis and Valley Fever can be life-threatening, particularly in immune-compromised patients. These patients also are more vulner...
Learn More
Learn More
Bruce Klein, Theodore Brandhorst, Thomas Sullivan, Marcel Wuethrich | P130116US02
Technology
Potential for Vaccine Against Johne’s Disease
Johne’s disease, or paratuberculosis, is a chronic and usually fatal wasting disease that is found worldwide and impacts more than half of the dairy herds in the U.S. alone. It costs the ruminan...
Learn More
Learn More
Adel Talaat | P130200US02
Technology
Safer Ebola Virus and Vaccines
Ebola is the deadliest virus on earth. It has caused death in 90 percent of cases during some outbreaks, afflicting human and great ape populations in tropical Africa. The virus is highly contagious i...
Learn More
Learn More
Yoshihiro Kawaoka, Peter Halfmann, Jin Hyun Kim | P07377US02
Technology
Safer Influenza Vaccine from Replication-Knock Out Virus
Influenza viruses instigate annual global epidemics. The first influenza pandemic in 40 years occurred during the 2009-2010 season, when a novel H1N1 strain emerged and spread worldwide. The United St...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Makoto Ozawa | P110003US02
Technology
Plasmids Encoding Avian Influenza Genes
Avian influenza causes significant economic losses for poultry producers worldwide and can be transmitted to humans and other mammals. The surface glycoproteins hemagglutinin (HA) and neuraminidase (N...
Learn More
Learn More
Yoshihiro Kawaoka | P06123US
Technology
High Titer Recombinant Influenza Viruses for Vaccines
Influenza is caused by the eight-segmented influenza virus. Vaccines can be used to prevent influenza, but traditional methods for producing influenza vaccine are slow and cumbersome.
To generate re...
Learn More
Learn More
Yoshihiro Kawaoka, Taisuke Horimoto, Shin Murakami | P06370US
Technology
High Titer Recombinant Influenza Viruses for Vaccines and Gene Therapy
Influenza is a major disease in humans that can be prevented by vaccination. Because new epidemic strains arise every year or two, the conventional influenza vaccine must be adapted almost every year,...
Learn More
Learn More
Yoshihiro Kawaoka | P03322US
Technology
Improved Reverse Genetics Method to Produce Influenza Virus
Influenza causes hundreds of thousands of deaths worldwide every year. Two of the genes critical for influenza virus infection are haemagglutinin (HA) and neuraminidase (NA). HA and NA are on the surf...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann | P04379US
Technology
Improved Production of Influenza Virus, Including H1N1, for Vaccine Manufacture
The H1N1 influenza virus, known as the “swine flu,” has been declared a pandemic. While this virus is less virulent than many circulating strains of flu virus, it has become the subj...
Learn More
Learn More
Yoshihiro Kawaoka, Taisuke Horimoto, Shin Murakami | P100078US02
Technology
Attenuated Influenza Viruses for Development of Live Influenza Vaccine
Influenza is a major disease in humans that can be prevented by vaccination. Because new epidemic strains arise every year or two, influenza vaccines must be adapted almost every year. Live atte...
Learn More
Learn More
Yoshihiro Kawaoka, Hatice Akarsu, Kiyoko Horimoto | P09022US02
Technology
Cell Line for Evaluating Influenza Virus Sensitivity to NA Inhibitors
The extensive use of neuraminidase (NA) inhibitors to treat influenza virus infections by reducing viral sialidase activity requires close monitoring for resistant variants. However, cultured cells do...
Learn More
Learn More
Yoshihiro Kawaoka | P05278US
Technology
Reverse Genetics Approach for Generating Ebola Virus and Other Filoviruses from Cloned DNA
Ebola virus, a negative strand RNA virus in the family Filoviridae, is among the most lethal human pathogens. Efforts to develop treatments for Ebola infections have been hampered by a lack of effecti...
Learn More
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Luke Jasenosky | P01214US
Technology
Nanoparticles That Target Dendritic Cells
Dendritic cells play an important role in the process of initiating immune response. They are present in small quantities in tissues, such as skin and lung, that are in contact with the external envir...
Learn More
Learn More
Ferencz Denes, Zsuzsanna Fabry, Matyas Sandor | P07026US
Technology
Methods and Compositions for Treating Prostate Cancer with DNA Vaccines
Prostate cancer is the second most common form of cancer among North American men. Current therapies for prostate cancer involve either removing the entire gland or treating it with radiation; however...
Learn More
Learn More
Douglas McNeel | P02376US
Technology
Novel Candidates for an Improved Tuberculosis Vaccine
Approximately one-third of the world’s population is infected with the bacterium Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). Five to 10 percent of non-immunocompr...
Learn More
Learn More
Adel Talaat, Bassam Abomoelak, Sarah Ward | P09203US02
Technology
Novel Peptide Adjuvant Improves Response to Influenza Vaccination
Influenza causes widespread morbidity and mortality worldwide. High-risk populations are routinely vaccinated in the United States, but influenza is still responsible for approximately 200,000 hospita...
Learn More
Learn More
Stacey Schultz-Cherry, Curtis Brandt, Jeremy Jones | P08262US